Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy

Michelle S. Parvatiyar, Alexandra J. Brownstein, Rosemeire Takeuchi, Judd R. Collado, Karissa M. Dieseldorff Jones, Jay Gopal, Katherine G. Hammond, Jamie L. Marshall, Abel Ferrel, Aaron M. Beedle, Jeffrey S. Chamberlain, Jose Renato Pinto, Rachelle H. Crosbie

Research output: Contribution to journalArticle

Abstract

In the current preclinical study, we demonstrate the therapeutic potential of sarcospan (SSPN) overexpression to alleviate cardiomyopathy associated with Duchenne muscular dystrophy (DMD) utilizing dystrophin-deficient mdx mice with utrophin haploinsufficiency that more accurately represent the severe disease course of human DMD. SSPN interacts with dystrophin, the DMD disease gene product, and its autosomal paralog utrophin, which is upregulated in DMD as a partial compensatory mechanism. SSPN-Tg mice have enhanced abundance of fully glycosylated α-dystroglycan, which may further protect dystrophin-deficient cardiac membranes. Baseline echocardiography revealed that SSPN improves systolic function and hypertrophic indices in mdx and mdx:utr-heterozygous mice. Assessment of SSPN-Tg mdx mice by hemodynamic pressure-volume methods highlighted enhanced systolic performance compared with mdx controls. SSPN restored cardiac sarcolemma stability, the primary defect in DMD disease; reduced fibrotic response; and improved contractile function. We demonstrate that SSPN ameliorated more advanced cardiac disease in the context of diminished sarcolemma expression of utrophin and β1D integrin, which mitigate disease severity, and partially restored responsiveness to β-adrenergic stimulation. Overall, our current and previous findings suggest that SSPN overexpression in DMD mouse models positively affects skeletal, pulmonary, and cardiac performance by addressing the stability of proteins at the sarcolemma that protect the heart from injury, supporting SSPN and membrane stabilization as a therapeutic target for DMD.

Original languageEnglish (US)
Article numbere123855
JournalJCI Insight
Volume4
Issue number11
DOIs
StatePublished - Jun 6 2019

Fingerprint

Sarcolemma
Duchenne Muscular Dystrophy
Cardiomyopathies
Utrophin
Dystrophin
Inbred mdx Mouse
Muscular Diseases
Dystroglycans
Heart Injuries
Haploinsufficiency
Membranes
Protein Stability
Integrins
Adrenergic Agents
Echocardiography
Heart Diseases
Hemodynamics
Pressure
Lung
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parvatiyar, M. S., Brownstein, A. J., Takeuchi, R., Collado, J. R., Dieseldorff Jones, K. M., Gopal, J., ... Crosbie, R. H. (2019). Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. JCI Insight, 4(11), [e123855]. https://doi.org/10.1172/jci.insight.123855

Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. / Parvatiyar, Michelle S.; Brownstein, Alexandra J.; Takeuchi, Rosemeire; Collado, Judd R.; Dieseldorff Jones, Karissa M.; Gopal, Jay; Hammond, Katherine G.; Marshall, Jamie L.; Ferrel, Abel; Beedle, Aaron M.; Chamberlain, Jeffrey S.; Pinto, Jose Renato; Crosbie, Rachelle H.

In: JCI Insight, Vol. 4, No. 11, e123855, 06.06.2019.

Research output: Contribution to journalArticle

Parvatiyar, MS, Brownstein, AJ, Takeuchi, R, Collado, JR, Dieseldorff Jones, KM, Gopal, J, Hammond, KG, Marshall, JL, Ferrel, A, Beedle, AM, Chamberlain, JS, Pinto, JR & Crosbie, RH 2019, 'Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy', JCI Insight, vol. 4, no. 11, e123855. https://doi.org/10.1172/jci.insight.123855
Parvatiyar MS, Brownstein AJ, Takeuchi R, Collado JR, Dieseldorff Jones KM, Gopal J et al. Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. JCI Insight. 2019 Jun 6;4(11). e123855. https://doi.org/10.1172/jci.insight.123855
Parvatiyar, Michelle S. ; Brownstein, Alexandra J. ; Takeuchi, Rosemeire ; Collado, Judd R. ; Dieseldorff Jones, Karissa M. ; Gopal, Jay ; Hammond, Katherine G. ; Marshall, Jamie L. ; Ferrel, Abel ; Beedle, Aaron M. ; Chamberlain, Jeffrey S. ; Pinto, Jose Renato ; Crosbie, Rachelle H. / Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy. In: JCI Insight. 2019 ; Vol. 4, No. 11.
@article{8e82872c88f5451c85eab3a595a9c86e,
title = "Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy",
abstract = "In the current preclinical study, we demonstrate the therapeutic potential of sarcospan (SSPN) overexpression to alleviate cardiomyopathy associated with Duchenne muscular dystrophy (DMD) utilizing dystrophin-deficient mdx mice with utrophin haploinsufficiency that more accurately represent the severe disease course of human DMD. SSPN interacts with dystrophin, the DMD disease gene product, and its autosomal paralog utrophin, which is upregulated in DMD as a partial compensatory mechanism. SSPN-Tg mice have enhanced abundance of fully glycosylated α-dystroglycan, which may further protect dystrophin-deficient cardiac membranes. Baseline echocardiography revealed that SSPN improves systolic function and hypertrophic indices in mdx and mdx:utr-heterozygous mice. Assessment of SSPN-Tg mdx mice by hemodynamic pressure-volume methods highlighted enhanced systolic performance compared with mdx controls. SSPN restored cardiac sarcolemma stability, the primary defect in DMD disease; reduced fibrotic response; and improved contractile function. We demonstrate that SSPN ameliorated more advanced cardiac disease in the context of diminished sarcolemma expression of utrophin and β1D integrin, which mitigate disease severity, and partially restored responsiveness to β-adrenergic stimulation. Overall, our current and previous findings suggest that SSPN overexpression in DMD mouse models positively affects skeletal, pulmonary, and cardiac performance by addressing the stability of proteins at the sarcolemma that protect the heart from injury, supporting SSPN and membrane stabilization as a therapeutic target for DMD.",
author = "Parvatiyar, {Michelle S.} and Brownstein, {Alexandra J.} and Rosemeire Takeuchi and Collado, {Judd R.} and {Dieseldorff Jones}, {Karissa M.} and Jay Gopal and Hammond, {Katherine G.} and Marshall, {Jamie L.} and Abel Ferrel and Beedle, {Aaron M.} and Chamberlain, {Jeffrey S.} and Pinto, {Jose Renato} and Crosbie, {Rachelle H.}",
year = "2019",
month = "6",
day = "6",
doi = "10.1172/jci.insight.123855",
language = "English (US)",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Stabilization of the cardiac sarcolemma by sarcospan rescues DMD-associated cardiomyopathy

AU - Parvatiyar, Michelle S.

AU - Brownstein, Alexandra J.

AU - Takeuchi, Rosemeire

AU - Collado, Judd R.

AU - Dieseldorff Jones, Karissa M.

AU - Gopal, Jay

AU - Hammond, Katherine G.

AU - Marshall, Jamie L.

AU - Ferrel, Abel

AU - Beedle, Aaron M.

AU - Chamberlain, Jeffrey S.

AU - Pinto, Jose Renato

AU - Crosbie, Rachelle H.

PY - 2019/6/6

Y1 - 2019/6/6

N2 - In the current preclinical study, we demonstrate the therapeutic potential of sarcospan (SSPN) overexpression to alleviate cardiomyopathy associated with Duchenne muscular dystrophy (DMD) utilizing dystrophin-deficient mdx mice with utrophin haploinsufficiency that more accurately represent the severe disease course of human DMD. SSPN interacts with dystrophin, the DMD disease gene product, and its autosomal paralog utrophin, which is upregulated in DMD as a partial compensatory mechanism. SSPN-Tg mice have enhanced abundance of fully glycosylated α-dystroglycan, which may further protect dystrophin-deficient cardiac membranes. Baseline echocardiography revealed that SSPN improves systolic function and hypertrophic indices in mdx and mdx:utr-heterozygous mice. Assessment of SSPN-Tg mdx mice by hemodynamic pressure-volume methods highlighted enhanced systolic performance compared with mdx controls. SSPN restored cardiac sarcolemma stability, the primary defect in DMD disease; reduced fibrotic response; and improved contractile function. We demonstrate that SSPN ameliorated more advanced cardiac disease in the context of diminished sarcolemma expression of utrophin and β1D integrin, which mitigate disease severity, and partially restored responsiveness to β-adrenergic stimulation. Overall, our current and previous findings suggest that SSPN overexpression in DMD mouse models positively affects skeletal, pulmonary, and cardiac performance by addressing the stability of proteins at the sarcolemma that protect the heart from injury, supporting SSPN and membrane stabilization as a therapeutic target for DMD.

AB - In the current preclinical study, we demonstrate the therapeutic potential of sarcospan (SSPN) overexpression to alleviate cardiomyopathy associated with Duchenne muscular dystrophy (DMD) utilizing dystrophin-deficient mdx mice with utrophin haploinsufficiency that more accurately represent the severe disease course of human DMD. SSPN interacts with dystrophin, the DMD disease gene product, and its autosomal paralog utrophin, which is upregulated in DMD as a partial compensatory mechanism. SSPN-Tg mice have enhanced abundance of fully glycosylated α-dystroglycan, which may further protect dystrophin-deficient cardiac membranes. Baseline echocardiography revealed that SSPN improves systolic function and hypertrophic indices in mdx and mdx:utr-heterozygous mice. Assessment of SSPN-Tg mdx mice by hemodynamic pressure-volume methods highlighted enhanced systolic performance compared with mdx controls. SSPN restored cardiac sarcolemma stability, the primary defect in DMD disease; reduced fibrotic response; and improved contractile function. We demonstrate that SSPN ameliorated more advanced cardiac disease in the context of diminished sarcolemma expression of utrophin and β1D integrin, which mitigate disease severity, and partially restored responsiveness to β-adrenergic stimulation. Overall, our current and previous findings suggest that SSPN overexpression in DMD mouse models positively affects skeletal, pulmonary, and cardiac performance by addressing the stability of proteins at the sarcolemma that protect the heart from injury, supporting SSPN and membrane stabilization as a therapeutic target for DMD.

UR - http://www.scopus.com/inward/record.url?scp=85070658234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070658234&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.123855

DO - 10.1172/jci.insight.123855

M3 - Article

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 11

M1 - e123855

ER -